As Global President of Inflammation & Immunology (I&I) at Pfizer, Mike Gladstone oversees a purpose-driven group of colleagues with deep experience and relationships in Rheumatology, Gastroenterology and Dermatology. Pfizer I&I is known for leading brands that are game-changers and mainstays of treatment that enable freedom for patients with chronic inflammatory diseases; these diseases can be debilitating, disfiguring and distressing, dramatically affecting what patients can do. Mike's career has spanned more than 25 years in the pharmaceutical industry at both Wyeth and Pfizer in the U.S. and Europe. Most recently, he was Global President of Internal Medicine at Pfizer, responsible for an $8 billion portfolio of medicines that targets the most prevalent health needs facing our society and includes cardio-metabolic and pain therapeutic areas. Mike is the Chairperson Elect for the U.S. Healthcare Leadership Council, where he serves as Treasurer and as a member of the Executive Committee representing pharmaceutical manufacturers. He is also on the Board of Directors of the Partnership for America's Health Care Future, Viiv Healthcare, and represents Pfizer on the Healthcare Businesswomen's Association's Gender Parity Collaborative. Previously, Mike served on the Board of the National Pharmaceutical Council.